PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: World cigarette statistics: Per capita consumption per year PART 06: Epidemiology • US PART 07: Health implications of smoking • Risk of tobacco smoke on non-smokers PART 08: Regulations on tobacco use • Impact of smoking bans on businesses • Economic benefits to individuals PART 09: Pipeline analysis • NAL2762 • X-22 • APD356 • GSK598809 • SEL-068 • ARD-1600 PART 10: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 11: Market segmentation by type • Global smoking cessation drugs market • Global NRTs market • Global e-cigarette market PART 12: Market segmentation by availability • Prescription products • OTC products PART 13: Geographical segmentation • Global smoking cessation products market by geography 2015-2020 • Smoking cessation products market in Americas • Smoking cessation products market in EMEA • Smoking cessation products market in APAC PART 14: Market drivers • Increase in number of smokers • Increase in teenage smoking • Significant number of public awareness programs • High awareness of risks associated with tobacco use PART 15: Impact of drivers PART 16: Market challenges • Side effects associated with drugs and therapies • Relapse after treatment • Weak R&D on drugs PART 17: Impact of drivers and challenges PART 18: Market trends • Increase in use of e-cigarettes • Increased innovation in smoking cessation products • Ban on tobacco advertisements • Increased pictorial warnings on cigarette packages PART 19: Vendor landscape • Competitive scenario • GlaxoSmithKline • Imperial Tobacco • NJOY • Pfizer • Reynolds American • Other prominent vendors PART 20: Appendix • List of abbreviations PART 21: Explore Technavio   List of Exhibits Exhibit 01: Product offerings Exhibit 02: Common health effects caused by smoking Exhibit 03: Smoking cessation products: Pipeline portfolio Exhibit 04: Discontinued projects Exhibit 05: Global smoking cessation products market 2015-2020 ($ billions) Exhibit 06: Five forces analysis Exhibit 07: Global smoking cessation products market by type Exhibit 08: Global smoking cessation products market by type 2015 Exhibit 09: Global smoking cessation drugs market 2015-2020 ($ billions) Exhibit 10: Global NRTs market 2015-2020 ($ billions) Exhibit 11: Global NRTs market by product 2015 Exhibit 12: Global nicotine patch market 2015-2020 ($ billions) Exhibit 13: Nicotine patch market by geographical region 2015 Exhibit 14: Global nicotine gum market 2015-2020 ($ billions) Exhibit 15: Nicotine gum market by geographical region 2015 Exhibit 16: Global e-cigarette market 2015-2020 ($ billions) Exhibit 17: Global e-cigarette market: Product life cycle analysis 2015 Exhibit 18: E-cigarette market by geographical region 2015 Exhibit 19: Global smoking cessation products market by availability Exhibit 20: Global smoking cessation products market by geography 2015 Exhibit 21: Global smoking cessation products market by geography 2020 Exhibit 22: Global smoking cessation products market revenue by geography 2015-2020 ($ billions) Exhibit 23: Smoking cessation products market in Americas 2015-2020 ($ billions) Exhibit 24: Smoking cessation products market in EMEA 2015-2020 ($ billions) Exhibit 25: Smoking cessation products market in APAC 2015-2020 ($ billions) Exhibit 26: Impact of drivers Exhibit 27: Impact of drivers and challenges Exhibit 28: Implementation of picture warnings in various countries Exhibit 29: GlaxoSmithKline: Business segmentation by revenue 2014 Exhibit 30: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 31: GlaxoSmithKline: Geographical segmentation by revenue 2014 Exhibit 32: GlaxoSmithKline: Key takeaways Exhibit 33: Imperial Tobacco: Business segmentation by revenue 2014 Exhibit 34: Imperial Tobacco: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 35: Imperial Tobacco: Key takeaways Exhibit 36: NJOY: Product categories Exhibit 37: NJOY: Key takeaways Exhibit 38: Pfizer: Business segmentation by revenue 2014 Exhibit 39: Pfizer: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 40: Pfizer: Geographical segmentation by revenue 2014 Exhibit 41: Pfizer: YoY growth and revenue of Chantix or Champix ($ millions) Exhibit 42: Pfizer: Key takeaways Exhibit 43: Reynolds American: Business segmentation by revenue 2014 Exhibit 44: Reynolds American: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 45: Reynolds American: Key takeaways

GlaxoSmithKline, Imperial Tobacco, NJOY, Pfizer, Reynolds American, 22nd Century Group, Alkalon, Altria Group, Aradigm, Arena Pharmaceuticals, Ballantyne Brands, British American Tobacco (BAT), CB Distributors, Cytos Biotechnology, Electronics Cigarettes International Group (Victory Electronic Cigarettes), Evotec, Gamucci, Japan Tobacco, Johnson & Johnson, LOGIC Technology, NAL Pharmaceuticals, Nicotek, Novartis, Revolymer, RR Chemicals, Selecta Biosciences, Target, The Harvard Drug Group, Vapor, VMR Products, Walgreens, Wal-Mart, White Cloud.